Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of SBRT and Docetaxel for Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Head and Neck

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Recurrent or second primary squamous cell head and neck cancer~* Defined area of recurrence on imaging~* Previous head and neck radiation (RT) to \>/= 50 Gy~* Performance status score 0-1~* Time interval from previous RT \>/= 9 months~* Volume of disease appropriate for protocol treatment~* Minimum estimated survival of \>/= 3 months~* Age \>/= 18~* Adequate labs~Exclusion Criteria:~* Primary tumors of the salivary gland~* Original pathology report and radiation therapy records not available~* Prior spinal cord dose \> 45 Gy~* Surgery or chemotherapy within 4 weeks~* Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years; noninvasive cancers are permitted

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Docetaxel + Stereotactic Radiation (Type: EXPERIMENTAL): Docetaxel 15mg/m2 IV weekly for 3 weeks. SBRT 25-40 Gy in 5 fractions given twice weekly with each treatment separated by \> 48 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).